Literature DB >> 17545385

Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity.

Nancy Chorne1, Carol Leonard, Robert Piecuch, Ronald I Clyman.   

Abstract

OBJECTIVES: The purpose of this work was to determine whether the reported association between neonatal morbidities and a patent ductus arteriosus is because of the left-to-right patent ductus arteriosus shunt itself, the therapies used to treat it, or the immaturity of the infants who are likely to develop a patent ductus arteriosus.
METHODS: A total of 446 infants (<28 weeks' gestation) were treated with the same patent ductus arteriosus care-oriented protocol, and logistic regression analysis was used to examine the effects of several patent ductus arteriosus-related variables (presence of a symptomatic patent ductus arteriosus, the number of indomethacin doses used, the ductus response to indomethacin, and the use of surgical ligation) on the incidence of retinopathy of prematurity, necrotizing enterocolitis, chronic lung disease, death, and neurodevelopmental impairment.
RESULTS: Most of the predictive effects that the presence of a patent ductus arteriosus and its treatment had on neonatal morbidity could be accounted for by the infants' immature gestation. Use of surgical ligation, however, was significantly associated with the development of chronic lung disease and was independent of immature gestation, other patent ductus arteriosus-related variables, or other perinatal and neonatal risk factors known to be associated with chronic lung disease.
CONCLUSIONS: These findings add to the growing uncertainty about the benefits and risks of surgical ligation during the neonatal period.

Entities:  

Mesh:

Year:  2007        PMID: 17545385     DOI: 10.1542/peds.2006-3124

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  54 in total

1.  Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants.

Authors:  Dany E Weisz; Lucia Mirea; Erin Rosenberg; Maximus Jang; Linh Ly; Paige T Church; Edmond Kelly; S Joseph Kim; Amish Jain; Patrick J McNamara; Prakesh S Shah
Journal:  JAMA Pediatr       Date:  2017-05-01       Impact factor: 16.193

Review 2.  Pathogenesis and treatment of bronchopulmonary dysplasia.

Authors:  Jason Gien; John P Kinsella
Journal:  Curr Opin Pediatr       Date:  2011-06       Impact factor: 2.856

3.  Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity.

Authors:  Ronald I Clyman; Melissa Liebowitz
Journal:  J Pediatr       Date:  2017-07-11       Impact factor: 4.406

4.  Patent ductus arteriosus: an overview.

Authors:  James E Dice; Jatinder Bhatia
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

5.  Patent ductus arteriosus: indomethacin, Ibuprofen, surgery, or no treatment at all?

Authors:  Peter Gal
Journal:  J Pediatr Pharmacol Ther       Date:  2009-01

6.  Does primary surgical closure of the patent ductus arteriosus in infants <1500 g or ≤32 weeks' gestation reduce the incidence of necrotizing enterocolitis?

Authors:  Wendy H Yee; Jeanne Scotland
Journal:  Paediatr Child Health       Date:  2012-03       Impact factor: 2.253

7.  Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome.

Authors:  Juliette C Madan; Douglas Kendrick; James I Hagadorn; Ivan D Frantz
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

Review 8.  General Anesthetics and Neurotoxicity: How Much Do We Know?

Authors:  Vesna Jevtovic-Todorovic
Journal:  Anesthesiol Clin       Date:  2016-09

9.  Factors affecting successful closure of hemodynamically significant patent ductus arteriosus with indomethacin in extremely low birth weight infants.

Authors:  Chuan-Zhong Yang; Jiun Lee
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

10.  Developing brain and general anesthesia - is there a cause for concern?

Authors:  Vesna Jevtovic-Todorovic
Journal:  F1000 Med Rep       Date:  2010-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.